Dopamine D2 receptor agonist, bromocriptine, remodels adipose tissue dopaminergic signalling and upregulates catabolic pathways, improving metabolic profile in type 2 diabetes

Background and objectives: The therapeutic effects of the dopamine D2 receptor (D2R) agonist, bromocriptine, in type 2 diabetes (T2D) have been attributed to central nervous system actions. However, peripheral dopamine directly modulates glucose uptake in insulin-sensitive tissues and lipid metaboli...

Full description

Bibliographic Details
Main Authors:	G. Tavares, D. Marques, C. Barra, D. Rosendo-Silva, A. Costa, T. Rodrigues, P. Gasparini, B.F. Melo, J.F. Sacramento, R. Seiça, S.V. Conde, P. Matafome
Format:	Article
Language:	English
Published:	Elsevier 2021-09-01
Series:	Molecular Metabolism
Subjects:	Type 2 diabetes Obesity Dopamine Bromocriptine D2 dopamine receptor Adipose tissue
Online Access:	http://www.sciencedirect.com/science/article/pii/S2212877821000867

Similar Items

Dopaminergic agonist bromocriptin in treatment of diabetes mellitus type 2
by: O A Gerasimenko, et al.
Published: (2011-12-01)

Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes
by: Via MA
Published: (2010-03-01)

Brain Dopamine–Clock Interactions Regulate Cardiometabolic Physiology: Mechanisms of the Observed Cardioprotective Effects of Circadian-Timed Bromocriptine-QR Therapy in Type 2 Diabetes Subjects
by: Anthony H. Cincotta
Published: (2023-08-01)

Incidence of heart valve disease in women treated with the ergot-derived dopamine agonist bromocriptine
by: Marianne F. Clausen, et al.
Published: (2021-12-01)

Bromocriptine and insulin sensitivity in lean and obese subjects
by: L Bahler, et al.
Published: (2016-11-01)

Effect of bromocriptine on glycemic control, risk of cardiovascular diseases and weight in patients with type 2 diabetes: a systematic review
by: Mulualem Tesfaye Birhan, et al.
Published: (2023-07-01)

Time-of-Day-Dependent Effects of Bromocriptine to Ameliorate Vascular Pathology and Metabolic Syndrome in SHR Rats Held on High Fat Diet
by: Michael Ezrokhi, et al.
Published: (2021-06-01)

Prolactinomas Resistant to Treatment With Dopamine Agonists: Long-Term Follow-Up of Six Cases
by: Maria de Fátima de Magalhães Gonzaga, et al.
Published: (2018-11-01)

The Mechanism and Pathways of Dopamine and Dopamine Agonists in Prolactinomas
by: Xiaoshuang Liu, et al.
Published: (2019-01-01)

Macroprolactinoma with secondary resistance to dopamine agonists: a case report and review of the literature
by: Eng-Loon Tng, et al.
Published: (2023-03-01)

The recurrence of prolactinoma after withdrawal of dopamine agonist: a systematic review and meta-analysis
by: Yunzhi Zou, et al.
Published: (2021-11-01)

An Increase in Peripheral Temperature following Cocaine Administration Is Mediated through Activation of Dopamine D2 Receptor in Rats
by: Suchan Chang, et al.
Published: (2022-01-01)

Bromocriptine does not alter speed-accuracy tradeoff
by: Jasper eWinkel, et al.
Published: (2012-08-01)

Are dopamine agonists still the first-choice treatment for prolactinoma in the era of endoscopy? A systematic review and meta-analysis
by: Xiangming Cai, et al.
Published: (2022-04-01)

Dopaminergic drug effects during reversal learning depend on anatomical connections between the orbitofrontal cortex and the amygdala.
by: Marieke E. van der Schaaf, et al.
Published: (2013-08-01)

Effect of cholestasis on Bromocriptine-induced yawning
by: Parviz M, et al.
Published: (1998-08-01)

Prolactinomas: evolution after menopause
by: Maria Susana Mallea-Gil, et al.

Evaluation of the efficacy and safety of bromocriptine QR in type 2 diabetes
by: Karuna Balwant Ramteke, et al.
Published: (2011-01-01)

Bromocriptine, a Dopamine (D2 ) Receptor Agonist, Used Alone and in Combination with Glipizide in Sub–Therapeutic Doses to Ameliorate Hyperglycaemia
by: Harish Kumar V.S., et al.
Published: (2013-09-01)

The regulatory effect of bromocriptine on cardiac hypertrophy by prolactin and D2 receptor modulation
by: Karla Aidee Aguayo-Cerón, et al.
Published: (2020-10-01)

Circulating Dopamine Is Regulated by Dietary Glucose and Controls Glucagon-like 1 Peptide Action in White Adipose Tissue
by: Gabriela Tavares, et al.
Published: (2023-01-01)

The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas
by: Shuman Wang, et al.
Published: (2021-11-01)

Selection in the dopamine receptor 2 gene: a candidate SNP study
by: Tobias Göllner, et al.
Published: (2015-08-01)

Evaluation of lipid profile and inflammatory parameters in female diabetes type 2 induced rabbits treated with glimepride,bromocriptine and fluoxtein
by: Duraid A. Abbas, et al.
Published: (2019-01-01)

A Case Report of Trigeminal Neuralgia after Taking Bromocriptine
by: Reza Bavarsad Shahripour
Published: (2011-07-01)

Effects of bromocriptine mesylate on homocysteine and high-sensitivity C-reactive protein levels in patients with type-2 diabetes mellitus
by: Mitra Niafar, et al.
Published: (2016-03-01)

Discovery research and development history of the dopamine D2 receptor partial agonists, aripiprazole and brexpiprazole
by: Tetsuro Kikuchi, et al.
Published: (2021-06-01)

Co-Administration of Curcumin and Bromocriptine Nano-liposomes for Induction of Apoptosis in Lung Cancer Cells
by: Mojgan Sheikhpour, et al.
Published: (2020-01-01)

Body weight changes in female patients with prolactinoma treated with bromocriptin
by: Z. Velija-Ašimi;
Published: (2007-08-01)

A peripartum cardiomyopathy case treated with bromocriptine
by: Dilek Yeşilbursa, et al.
Published: (2021-03-01)

Bromocriptine in type 2 diabetes mellitus
by: C Shivaprasad, et al.
Published: (2011-01-01)

Antiangiogenic Effect of Dopamine and Dopaminergic Agonists as an Adjuvant Therapeutic Option in the Treatment of Cancer, Endometriosis, and Osteoarthritis
by: Julieta Griselda Mendoza-Torreblanca, et al.
Published: (2023-06-01)

Circadian‐timed quick‐release bromocriptine lowers elevated resting heart rate in patients with type 2 diabetes mellitus
by: Bindu Chamarthi, et al.
Published: (2020-01-01)

Experience with Dopamine Agonists in the Treatment of Prolactinomas
by: Nadiya Barabash, et al.
Published: (2022-11-01)

Repurposing of Bromocriptine for Cancer Therapy
by: Ean-Jeong Seo, et al.
Published: (2018-10-01)

Serum prolactin level in chronic urticaria: Is bromocriptine inducing remission in chronic urticaria?
by: Mohamed Soliman, et al.
Published: (2018-11-01)

Dopamine-induced astrocytic Ca2+ signaling in mPFC is mediated by MAO-B in young mice, but by dopamine receptors in adult mice
by: Sunpil Kim, et al.
Published: (2022-11-01)

Dopamine D2-Subtype Receptors Outside the Blood-Brain Barrier Mediate Enhancement of Mesolimbic Dopamine Release and Conditioned Place Preference by Intravenous Dopamine
by: J. Daniel Obray, et al.
Published: (2022-07-01)

Successful treatment of dopamine dysregulation syndrome with dopamine D<sub>2</sub> partial agonist antipsychotic drug
by: Mizushima Jin, et al.
Published: (2012-07-01)

Role of bromocriptine in multi-spectral manifestations of traumatic brain injury
by: Sunil Munakomi, et al.
Published: (2017-04-01)